This stimulating symposium is designed to challenge the experts and attendees regarding tailoring endocrine and bisphosphonate therapies to optimize outcomes for early breast cancer. “Pattern of Practice” questions will explore areas of controversy regarding these therapies. Updates on evolving strategies for adjuvant endocrine therapy, the antitumor activity of bisphosphonates as well as the role of markers of bone metabolism in metastatic disease will provide information that could change the scope of current patterns of practice.

Target Audience
This educational activity is intended for medical oncologists, surgical oncologists, radiation oncologists, and other healthcare professionals with an interest in new developments in breast cancer.

Statement of Need
Despite the tremendous strides made in the treatment of breast cancer, differences in the management and outcome of select groups remain. Breast cancer includes a variety of complex disease states with equally complex approaches to clinical care. For example, recent studies have confirmed significant reduction in risk of recurrence associated with adjuvant endocrine therapies, but the numerous choices created confusion regarding “optimal” therapy or sequencing of therapies. Another challenge healthcare providers are faced with is treatment and prevention of metastatic disease, with bone being the most common site. This program focuses on the growing body of evidence from preclinical and clinical research showing the antitumor activity of bisphosphonates and the potential role of elevated markers of bone metabolism in prevention of bone metastasis. The lack of consensus on optimal patient treatments pinpoints the need for continuing education regarding management of early breast cancer.

Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Explain the potential role of bisphosphonates in prevention of bone metastasis in breast cancer patients
• Review the latest preclinical data supporting the antitumor activity of bisphosphonates
• Identify the significance of elevated markers of bone metabolism in patients with breast cancer
• Discuss updated clinical trials data regarding optimal treatment strategies for adjuvant endocrine therapy in postmenopausal breast cancer patients

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and PRIME Oncology. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
PIM designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
PIM and PRIME Oncology assess conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM and PRIME Oncology for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. PIM and PRIME Oncology are committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).
Please contact Kim Friese prior to the live event at (678) 892-1340 or kim.friese@primeoncology.org.

Rob Coleman, MD (Chair)
Professor of Medical Oncology
Cancer Research Centre
Weston Park Hospital
Sheffield, United Kingdom

Kimberly Blackwell, MD
Division of Hematology-Oncology
Duke University Medical Center
Durham, North Carolina

Michael Gnant, MD
Professor of Surgery
University of Vienna
Vienna, Austria


Hope Rugo, MD
Clinical Professor of Medicine
Division of Hematology & Oncology
Director, Breast Cancer Clinical Trials Program
University of California San Francisco
San Francisco, California, USA


Beat J.K. Thürlimann, MD
Head, Breast Center
Kantonsspital
St. Gallen, Switzerland

7:30 pm-7:45 pm	Registration and Dinner
7:45 pm-7:50 pm	Welcome and Introduction Rob Coleman, MD
7:50 pm-8:10 pm	Bisphosphonates and Breast Cancer: Exploring the Opportunities Rob Coleman, MD
8:10 pm-8:40 pm	Taking Preclinical Observations Into the Clinic: Current Adjuvant Bisphosphonate Trials Michael Gnant, MD Rob Coleman, MD
8:40 pm-9:00 pm	Evolving Strategies for Adjuvant Endocrine Therapy: An Interim Analysis of the BIG 1-98 Trial Beat J.K Thürlimann, MD
9:00 pm-9:40 pm	Optimal Management of Early Breast Cancer: Challenging the Experts Rob Coleman, MD Kimberly Blackwell, MD Michael Gnant, MD Hope Rugo, MD Beat J.K. Thürlimann, MD
9:40 pm-9:45 pm	Concluding Remarks Rob Coleman, MD